Benzinga
Benzinga
Benzinga
martedì, settembre 22

Pfizer Inc

PFENYSE
Trade with Public
Trade with Public
$27.74
0.080.29%
In chiusura: Sep 18, 5:00 PM EST
$27.68
0.020.07%
Pre-mercato: 6:31 AM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Pfizer Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pfizer (PFE).

Price Target Range — 12 Quarters

Analyst Consensus — 19 Analysts

7Buy
10Hold
2Sell
Consensus RatingNeutral# Analysts19Avg. Consensus PT$30Upside to Avg. PT+8.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 10, 2026HSBCRajesh KumarPT RaiseHold$28→$30
Aug 7, 2026GuggenheimVamil DivanPT CutBuy$35→$31
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HSBC Maintains Hold on Pfizer, Raises Price Target to $30

HSBC analyst Rajesh Kumar maintains Pfizer (NYSE:PFE) with a Hold and raises the price target from $28 to $30.
Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: Pfizer, Nvidia, Take-Two Interactive Software, Cheniere Energy

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.
Avi Kapoor

PRO
Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $31

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target from $35 to $31.
Benzinga Newsdesk

Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenue at $14.39B. Stock rose 0.1% on Monday.
Avi Kapoor

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.
Vandana Singh

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved